Johnson & Johnson Bolsters Its Oncology Pipeline With Nanobiotix Radiotherapy Pact
Portfolio Pulse from Vandana Singh
Nanobiotix (NBTX) has entered into a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, a unit of Johnson & Johnson (JNJ), for the investigational radioenhancer NBTXR3. Janssen will pay $60 million in upfront fees and funding for an exclusive worldwide license. The agreement also includes potential milestone payments of up to $650 million for five new indications that Janssen may develop, and up to $220 million per indication that Nanobiotix may develop in alignment with Janssen.
July 10, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's unit, Janssen Pharmaceutica NV, has entered into a global licensing agreement with Nanobiotix for NBTXR3. This bolsters J&J's oncology pipeline and could potentially lead to the development of new treatments.
The agreement with Nanobiotix allows Janssen Pharmaceutica NV to bolster its oncology pipeline, which could potentially lead to the development of new treatments. This is likely to have a positive short-term impact on Johnson & Johnson's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The agreement with Janssen Pharmaceutica NV is a significant development for Nanobiotix, which could potentially receive up to $870 million in milestone payments. This has led to a surge in the company's stock price.
The agreement with Janssen Pharmaceutica NV provides Nanobiotix with a significant financial boost, with potential milestone payments of up to $870 million. This positive news has led to a surge in the company's stock price, indicating a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100